Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update


PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results for the fiscal second quarter ended April 30, 2019. Key updates on the progress of the company’s clinical pipeline include the following: ADXS-NEO: Personalized, Neoantigen-Directed Therapy – The company is currently enrolling patients in it ….